Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
1270 articles with Regeneron Pharmaceuticals, Inc.
Sanofi-Aventis (France) and Regeneron Pharmaceuticals, Inc. Results of VEGF Trap (Aflibercept) Highlighted at American Society of Clinical Oncology 2007 Annual Meeting
Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis (France) Release: Results of VEGF Trap (Aflibercept) Highlighted at American Society of Clinical Oncology 2007 Annual Meeting
Regeneron Pharmaceuticals, Inc.: VEGF Trap-Eye Phase 2 Wet AMD Results Reported at Association for Research in Vision & Ophthalmology Annual Meeting
Regeneron Pharmaceuticals, Inc. Announces Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Regeneron Pharmaceuticals, Inc. Release: Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc. to Present at Lehman Brothers 10th Annual Global Healthcare Conference
Regeneron Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2006 Financial and Operating Results
Regeneron Pharmaceuticals, Inc. Release: IL-1 Trap Phase 3 Trial Data Presented at Annual Meeting of American Academy of Allergy, Asthma and Immunology (AAAAI)
Regeneron Pharmaceuticals, Inc. Expands Commercial and Clinical Capabilities Through New Hires and Promotions
Regeneron Pharmaceuticals, Inc. Announces VEGF Trap Clinical Update; Collaborating With Sanofi-Aventis (France)
Regeneron Pharmaceuticals, Inc. Announces Presentation At 25th Annual JPMorgan Healthcare Conference
Regeneron Pharmaceuticals, Inc. Reports Blocking New Angiogenesis Target May Offer Novel Approach To Slowing Tumor Growth
Regeneron Pharmaceuticals, Inc. Announces Participation In Panel Discussions At RBC Capital Markets Conference
Regeneron Pharmaceuticals, Inc. Announces Presentation At Rodman & Renshaw 8TH Annual Healthcare Conference
Bayer HealthCare AG And Regeneron Pharmaceuticals, Inc. To Collaborate On VEGF Trap For The Treatment Of Eye Diseases; Regeneron Retains U.S. Commercialization Rights, Receives $75 Million Upfront, And Eligible For Up To $245 Million Of Milestone Payments